Kinase Inhibitor [EPC]

422499 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS SORAFENIB PALBOCICLIB GEFITINIB ACALABRUTINIB AXITINIB LAROTRECTINIB LORLATINIB VANDETANIB ABEMACICLIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 48254
1 FATIGUE 37888
2 DIARRHOEA 33795
3 OFF LABEL USE 24676
4 NAUSEA 24170
5 RASH 15716
6 ASTHENIA 14986
7 MALIGNANT NEOPLASM PROGRESSION 14814
8 DECREASED APPETITE 14645
9 DYSPNOEA 13904
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 258 0.8600
1 CYTOGENETIC ANALYSIS ABNORMAL 433 0.4988
2 NEOPLASM PROGRESSION 13339 0.4791
3 ACQUIRED GENE MUTATION 437 0.4600
4 CHRONIC MYELOID LEUKAEMIA RECURRENT 172 0.4000
5 TRANSPLANT DYSFUNCTION 500 0.3605
6 CARBOHYDRATE ANTIGEN 15-3 INCREASED 175 0.3458
7 HAEMATOCRIT ABNORMAL 324 0.3309
8 TUMOUR MARKER INCREASED 1098 0.3131
9 HEPATOCELLULAR CARCINOMA 1888 0.3053
See all enriched reactions for Kinase Inhibitor [EPC]